SCHEMBL554462

SCHEMBL554462

CC(C)(C)c1cc(Oc2c(I)cc(CCC(=O)O)cc2I)cc(C(C)(C)C)c1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCNA P12004 7/20 0.62
THRB P10828 6/20 0.60
THRA P10827 5/20 0.60
POLB P06746 2/20 0.60
HIF1A Q16665 2/20 0.60
MAPK1 P28482 1/20 0.60
PPARG P37231 4/20 0.56
RXRA P19793 3/20 0.56
ITGB3 P05106 1/20 0.56
ITGAV P06756 1/20 0.56
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
LMNA P02545 3/20 0.47
ADORA3 P0DMS8 3/20 0.47
PDE4D Q08499 3/20 0.47
HSD17B10 Q99714 3/20 0.47
TTR P02766 2/20 0.47
CYP1A2 P05177 2/20 0.47
HTR1A P08908 2/20 0.47
CYP2C9 P11712 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4238467 0.86 THRB (0.73) PCNATHRBTHRAPOLBHIF1A
SCHEMBL27709526 0.82 GAA (0.54) PCNATHRBTHRAPOLBHIF1A
SCHEMBL16425259 0.81 PCNA (0.68) PCNATHRBTHRAPOLBHIF1A
SCHEMBL39190 0.80 GAA (0.66) HIF1AMAPK1RXRAKMT2AMEN1
SCHEMBL12440046 0.79 PCNA (0.69) PCNATHRBTHRAPOLBHIF1A
Ethylene Glycol SCHEMBL208762 0.79 GAA (0.60) HIF1AMAPK1RXRAKMT2AMEN1
Ammonia Solution, Strong SCHEMBL4047307 0.79 GAA (0.64) HIF1AMAPK1RXRAKMT2AMEN1
Hydrochloric Acid SCHEMBL7945960 0.79 GAA (0.64) HIF1AMAPK1RXRAKMT2AMEN1
SCHEMBL11368092 0.79 GAA (0.64) HIF1AMAPK1RXRAKMT2AMEN1
Methane SCHEMBL2168088 0.79 GAA (0.64) HIF1AMAPK1RXRAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122057009-A Use of Hinderin protein for regulating cilia length 重庆医科大学 2026-05-19 CN claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
WO-1994018552-A1 MULTIPLEXED FLUORESCENCE DETECTOR SYSTEM FOR CAPILLARY ELECTROPHORESIS IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 1994-08-18 WO claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed
CN-122057009-A Use of Hinderin protein for regulating cilia length 重庆医科大学 2026-05-19 CN disclosed
CN-122057009-A Use of Hinderin protein for regulating cilia length 重庆医科大学 2026-05-19 CN disclosed
CN-122057009-A Use of Hinderin protein for regulating cilia length 重庆医科大学 2026-05-19 CN disclosed
EP-3950417-B1 SIDE TO SIDE TILTING AIRCRAFT SEAT MECHANISM AMI IND INC (US) 2025-11-26 EP disclosed
US-12473594-B2 Chemical tagging-based method for modified nucleoside sequencing, enrichment, and measurement PEKING UNIVERSITY (CN) 2025-11-18 US disclosed
US-12452356-B2 Communication apparatus, method, and program having a signal strength compass Sony Group Corporation (JP) 2025-10-21 US disclosed
US-20250259852-A1 TOOL AND PROCESSES FOR ELECTROCHEMICAL ETCHING BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-08-14 US disclosed
US-5719197-A DRUG DELIVERY NOVEN PHARMACEUTICALS, INC. (US) 1998-02-17 US disclosed
US-5656286-A BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE NOVEN PHARMACEUTICALS, INC. (US) 1997-08-12 US disclosed
WO-1996040084-A1 COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT NOVEN PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
WO-1996040086-A2 COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS NOVEN PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
US-5446070-A Flexible, finite, bioadhesive, therapeutical agent in solid form NOVER PHARMACEUTICALS, INC. (US) 1995-08-29 US disclosed
US-5001115-A Prodrugs of biologically active hydroxyaromatic compounds UNIVERSITY OF FLORIDA (US) 1991-03-19 US disclosed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473594-B2 Chemical tagging-based method for modified nucleoside sequencing, enrichment, and measurement NT5C3B, BHMT2, NNMT PCNA 117/4885THRB 1431/4885THRA 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.